Session 5: 3Rs statement VICH5 Conference, October 2015, Tokyo 1.

Slides:



Advertisements
Similar presentations
EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.
Advertisements

EPAA Annual Conference 2007 Regulatory Acceptance and Implementation of 3Rs approaches Challenges for industry and regulators Dr. Hennicke Kamp BASF Aktiengesellschaft.
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
1 Development, Implementation and Use of Alternative Test Methods in Regulatory Hazard Assessment in OECD Member countries Herman B.W.M.Koëter, Principal.
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
1 Animal Research for the Industry: Scientific Merit by a Multilateral Review Simon Authier, D.V.M., M.Sc., M.B.A. Head of Veterinary Services LAB Research.
The work of ethical review committees in Germany and the United Kingdom - from the point of view of animal welfare Ursula G. Sauer, Germany For: Royal.
CONTROVERSIES AND ETHICS OF ANIMAL TESTING: EMERGING ISSUES AND NEW CHALLENGES By Prof. Dr. P. V. S. KISHORE, Ph.D., FNAVS, FIAVA Professor & Head Department.
Value of in vitro assays in your REACH dossier Frédérique van Acker 18 November 2014.
Evolution of ICCVAM ◊National Toxicology Program Develop and validate improved test methods ◊NIH Revitalization Act: P.L Develop and.
Sara Paradowski – AEC Secretary Research Governance Unit.
Ethical Treatment of Lab Animals
DENNIS CRYER Veterinary Meat Hygiene Adviser Food Standards Agency
Psychology 291 – Lab 4 Ethics October 9, 2012
The Use of Animals in Research Is a Privilege We Wish to Retain Animal Welfare Versus Animal Rights How are Animal Welfare Concerns Reported?
Phil 7570, Fall 2007 Bryan Benham The Ethical Challenge of Animal Experimentation 1.
6. Strategic Plan : Implementing GEOSS Validating the way forward: Review of feedback from Plenary.
Institutional Animal Care and Use Committee. IACUC  Required by AWA, PHS, AAALAC  Is appointed by the President of the UA  The Institutional Official.
*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.
The Science of Alternatives: Initial Truths— Current Realities January, 2008 Alan M. Goldberg, Ph.D. Johns Hopkins University Bloomberg School of Public.
The 3Rs principles in the revised Directive 2010/63 – industry position Karin Blumer, Novartis & Magda Chlebus, EFPIA Ecopa/CAAT Europe, 31 January 2011.
Unit 3 – Health psychology: substance misuse The use of animals in drug research.
Animals in Research Donald B. Casebolt Director, Department of Animal Resources.
European Commission - DG Environment Directive 2010/63/EU on the protection of animals used for scientific purposes “Opportunities and challenges” Berlin,
FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.
Animal Use in Biomedical Research October 5, 2015.
8 th November 2007 Research: ethics and research governance Rossana Dowsett Research and Regional Development Division [Pre Award Support] University of.
An agency of the European Union Presented by: Kornelia Grein Role of VICH and VICH guidelines in marketing authorizations 2 nd VICH Outreach Forum meeting,
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
E-Clinical
Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Challenges of Developing VICH Guidance for Residue Studies in Food Producing Aquatic Species Pamela Boner, Zoetis Session 7: VICH Conference Tokyo, Japan:
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.
How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.
Training and competence of people Bryan Howard. Today I will use the word competence to signify: The possession of suitable and sufficient skill, knowledge,
DR PENNY HAWKINS RSPCA RESEARCH ANIMALS DEPARTMENT Identifying and reducing sources of suffering during procedures, including avoiding severe suffering.
1 THE OIE REPORT 32 nd VICH SC Meeting / 6 th VICH Outreach Forum Meeting Jean-Pierre Orand, Anses, France, OIE Collaborating Centre.
How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Issues Batch safety testing for vaccines
VICH General Principles and
Requirements for GLP and GCP in the EU
Genetic Engineering and Animal Research
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Research Ethics Matthew Billington
Waiving Target Animal Batch Safety Testing for vaccines
The 3Rs principles for safety testing of human and veterinary medicines A view on the EU regulatory developments in 3Rs (replacement, reduction, refinement)
The expectations from VICH Outreach Forum members
How Can I Get More Information on VICH?
The Benefits of VICH to Emerging Countries
GL50(R)- HARMONISATION OF CRITERIA TO WAIVE TARGET ANIMAL BATCH SAFETY TESTING FOR INACTIVATED VACCINES FOR VETERINARY USE ( May 2017) GL55- HARMONISATION.
University of Windsor Animal User Training Program
Quality guidelines on impurities
Quality guidelines on impurities
VICH Guidelines on stability: OVERVIEW
Abnormal toxicity test (ATT) -
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Session 5: 3Rs statement VICH5 Conference, October 2015, Tokyo 1

The 3Rs: Replacement Reduction Refinement of animals used for regulatory testing The 3Rs: Replacement Reduction Refinement of animals used for regulatory testing 2

3Rs: Replacement, Refinement, Reduction Replacement: testing approaches that avoid or replace the use of live animals (eg, in-vitro tests) Reduction: approaches that minimise the number of animals being used (eg, by maximising the information obtained per animal) Refinement: modification of a procedure to minimise the pain, suffering, distress or lasting harm experienced by the animal (eg, use of anaesthetics) 3

Animal welfare Ethical and animal welfare considerations require animal use to be limited as much as possible Harmonisation of requirements means that the same animal studies are acceptable in different regions - avoids unnecessary tests VICH goes beyond that… 4

A VICH objective The VICH will: Establish and implement harmonized technical requirements for the registration of veterinary medicinal products in the VICH regions, which meet high quality, safety and efficacy standards and minimise the use of test animals and costs of product development. … 5

Statement of principle In 2007, the VICH Steering Committee agreed a “Statement of principle on 3Rs”, expressing support for the 3Rs principle and recognising that its international status and influence provides a unique opportunity to encourage the use of alternative methods Reflected in organizational charter: Expert Working Groups developing guidelines involving animal testing have a specific responsibility to consider the possibilities for replacement, reduction and refinement of animal testing => VICH guidelines are written – and updated – with the 3Rs considerations firmly in mind 6

Examples VICH GL32 – Developmental toxicity testing: – A tiered approach: testing only required in second species if no teratogenicity seen in first species VICH GL48 – Marker residue depletion studies to establish product withdrawal periods – If withdrawal period will clearly be driven by injection site, then two injections can be administered per animal (on different days) in order to obtain injection site data from two time points per animal VICH GL47 – Laboratory animal comparative metabolism studies – Use of in vitro metabolism tests (primary hepatocytes, liver microsomes, whole cells…) in examining metabolite profile 7

3Rs concerns may be the driver VICH GL23(R) – genotoxicity testing – Considering the need for a default in vivo test VICH GL22 – reproduction toxicity – Investigate the case for allowing an extended one generation reproduction toxicity study as alternative to 2 generation test VICH GL50 – harmonisation of criteria to waive TABST for inactivated vaccines – After 10 batches the test can be waived 8

VICH in 3Rs VICH has a positive role to play in relation to 3Rs: Harmonisation of data requirements reduces repetitious testing and the number of animals used VICH requires consideration of 3Rs in development of its guidelines 9

VICH Statement of Principle At its 19th meeting on January 2007 in Washington D.C., USA, the VICH Steering Committee reiterated its ambition to minimise animal testing and specifically expressed its support for the 3Rs principle – replacement, refinement and reduction of animals in research. VICH has always striven to eliminate repetitious and unnecessary testing through harmonisation of regulatory requirements for the registration of veterinary products, a goal that undoubtedly leads to a reduction in the number of animals used for product development and registration. While the validation of alternative testing protocols falls outside the remit of VICH, the Steering Committee recognises that the international status and influence of VICH provide a unique opportunity to encourage the use of validated alternative methods. To this end, Expert Working Groups developing guidelines involving animal experimentation have a specific responsibility to consider animal welfare, and particularly the possibilities for replacement, refinement and reduction of animal testing 10

11 The VICH public website ( 11

12 Thank you